Who is sponsoring NCT01248819?

NCT01248819 is sponsored by San Gerardo Hospital.

What condition does NCT01248819 study?

NCT01248819 studies Laparoscopic Cholecystectomy.

What drugs are being tested in NCT01248819?

Interventions: Ropivacaine 60 mg, Ropivacaine 100 mg.

What is the status of NCT01248819?

NCT01248819 is currently COMPLETED.

Last reviewed 2010-11-24 · How we verify

Double Blind Randomized Phase III Controlled Trial Comparing the Effect of Intraperitoneal Nebulization of Ropivacaine With Intraperitoneal Instillation of Ropivacaine on Pain Control After Laparoscopic Cholecystectomy

NCT01248819 Phase 3 COMPLETED

Studies evaluating intraperitoneal local anesthetic instillation for pain relief after laparoscopic procedures have provided conflicting results. This randomized, double-blind study was designed to assess the effects of a novel intraperitoneal local anesthetic administration technique using nebulization on pain relief after laparoscopic cholecystectomy.

Details

Lead sponsor	San Gerardo Hospital
Phase	Phase 3
Status	COMPLETED
Enrolment	60
Start date	2008-04
Completion	2009-05

Conditions

Laparoscopic Cholecystectomy

Interventions

Ropivacaine 60 mg
Ropivacaine 100 mg

Primary outcomes

Postoperative Pain — 48 hours
Postoperative pain was assessed by Visual analgue scale (VAS 0 to 100 points) at rest (static VAS) and after a deep inspiration or cough (dynamic VAS). The proportion of patients with adequate pain control after surgery (dynamic VAS \< 3) will also be assessed.

Countries

Italy